Catabasis raises $32M to advance hypertriglyceridemia drug

11/18/2013 | American City Business Journals

Catabasis Pharmaceuticals has raised $32 million in its latest funding round and hired former JSB-Partners adviser Ian Sanderson to become its new chief financial officer. The Cambridge, Mass.-based firm said the money will be used for the midstage trials of its hypertriglyceridemia drug candidate CAT-2003.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations